1.An online evaluation of problem-based learning (PBL) in Chung Shan Medical University, Taiwan - a pilot study.
Jia-Yuh CHEN ; Meng-Chih LEE ; Hong-Shan LEE ; Yeou-Chih WANG ; Long-Yau LIN ; Jen-Hung YANG
Annals of the Academy of Medicine, Singapore 2006;35(9):624-633
INTRODUCTIONProblem-based learning (PBL) embraces principles of good learning and teaching. It is student-directed, fosters intrinsic motivation, promotes active learning, encourages peer teaching, involves timely feedback, and can support student self and peer assessment. The most important function of the assessment process is to enhance student learning, to improve the curriculum and to improve teaching.
MATERIALS AND METHODSTo improve the PBL tutorial in Chung Shan Medical University, we developed an online evaluation system containing the evaluation forms for students, tutor, self and peer. The Cronbach alpha reliability coefficients were 0.9480, 0.9103, and 0.9198 for the Student, Tutor and Self and Peer Evaluation Form, respectively. The online evaluations were mandatory to both students and tutors, and the information was completely anonymous.
RESULTS AND CONCLUSIONSThe survey response rates of the online evaluations ranged from 95.6% to 100%. The online evaluations provided a documented feedback to the students on their knowledge, skills and attitudes. Correspondingly, tutors too received feedback from students in evaluating their performance on the appropriateness and effectiveness of tutoring the group. Although there was an initial lack of coordination regarding responsibilities and how to use the online system for both students and the Faculty, the system enabled us to look into how effective our PBL course had been, and it provided both process and outcome evaluations. Our strategy for evaluating the success of PBL is only at its initial stage; we are in an ongoing process of collecting outcome data for further analysis which will hopefully provide more constructive information to the PBL curricula.
Education, Medical ; standards ; Educational Measurement ; Humans ; Online Systems ; Pilot Projects ; Problem-Based Learning ; methods ; Taiwan ; Universities
3.Early-life exposure to endocrine disrupting chemicals associates with childhood obesity.
Chunxue YANG ; Hin Kiu LEE ; Alice Pik Shan KONG ; Lee Ling LIM ; Zongwei CAI ; Arthur C.K CHUNG
Annals of Pediatric Endocrinology & Metabolism 2018;23(4):182-195
Increasing prevalence of childhood obesity poses threats to the global health burden. Because this rising prevalence cannot be fully explained by traditional risk factors such as unhealthy diet and physical inactivity, early-life exposure to endocrine disrupting chemicals (EDCs) is recognized as emerging novel risk factors for childhood obesity. EDCs can disrupt the hormone-mediated metabolic pathways, affect children’s growth and mediate the development of childhood obesity. Many organic pollutants are recently classified to be EDCs. In this review, we summarized the epidemiological and laboratory evidence related to EDCs and childhood obesity, and discussed the possible mechanisms underpinning childhood obesity and early-life exposure to non-persistent organic pollutants (phthalates, bisphenol A, triclosan) and persistent organic pollutants (dichlorodiphenyltrichloroethane, polychlorinated biphenyls, polybrominated diphenyl ethers, per- and polyfluoroalkyl substances). Understanding the relationship between EDCs and childhood obesity helps to raise public awareness and formulate public health policy to protect the youth from exposure to the harmful effects of EDCs.
Adolescent
;
Diet
;
Endocrine Disruptors*
;
Global Health
;
Halogenated Diphenyl Ethers
;
Humans
;
Metabolic Networks and Pathways
;
Pediatric Obesity*
;
Polychlorinated Biphenyls
;
Prevalence
;
Public Health
;
Risk Factors
4.Inhibition of Human Pancreatic Tumor Growth by Cytokine-Induced Killer Cells in Nude Mouse Xenograft Model.
Ji Sung KIM ; Yun Soo PARK ; Ju Young KIM ; Yong Guk KIM ; Yeon Jin KIM ; Hong Kyung LEE ; Hyung Sook KIM ; Jin Tae HONG ; Youngsoo KIM ; Sang Bae HAN
Immune Network 2012;12(6):247-252
Pancreatic cancer is the fourth commonest cause of cancer-related deaths in the world. However, no adequate therapy for pancreatic cancer has yet been found. In this study, the antitumor activity of cytokine-induced killer (CIK) cells against the human pancreatic cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 for 14 days. The resulting populations of CIK cells comprised 94% CD3+, 4% CD3-CD56+, 41% CD3+CD56+, 11% CD4+, and 73% CD8+. This heterogeneous cell population was called cytokine-induced killer (CIK) cells. At an effector-target cell ratio of 100:1, CIK cells destroyed 51% of AsPC-1 human pancreatic cancer cells, as measured by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 42% and 70% of AsPC-1 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for pancreatic cancer patients.
Animals
;
Cytokine-Induced Killer Cells
;
Humans
;
Immunotherapy, Adoptive
;
Mice
;
Mice, Nude
;
Pancreatic Neoplasms
;
Transplantation, Heterologous
5.Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells.
Ji Sung KIM ; Yong Guk KIM ; Minji PYO ; Hong Kyung LEE ; Jin Tae HONG ; Youngsoo KIM ; Sang Bae HAN
Immune Network 2015;15(2):58-65
Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity.
Cell- and Tissue-Based Therapy*
;
Cytokine-Induced Killer Cells*
;
Drug Resistance
;
Heterografts
;
Humans
;
Incidence
;
Lymphocytes, Tumor-Infiltrating
;
Melanoma*
;
Prognosis
;
Protein-Tyrosine Kinases
;
Skin Neoplasms
;
Survival Rate
6.Preclinical Efficacy and Mechanisms of Mesenchymal Stem Cells in Animal Models of Autoimmune Diseases.
Hong Kyung LEE ; Sang Hee LIM ; In Sung CHUNG ; Yunsoo PARK ; Mi Jeong PARK ; Ju Young KIM ; Yong Guk KIM ; Jin Tae HONG ; Youngsoo KIM ; Sang Bae HAN
Immune Network 2014;14(2):81-88
Mesenchymal stem cells (MSCs) are present in diverse tissues and organs, including bone marrow, umbilical cord, adipose tissue, and placenta. MSCs can expand easily in vitro and have regenerative stem cell properties and potent immunoregulatory activity. They inhibit the functions of dendritic cells, B cells, and T cells, but enhance those of regulatory T cells by producing immunoregulatory molecules such as transforming growth factor-beta, hepatic growth factors, prostaglandin E2, interleukin-10, indolamine 2,3-dioxygenase, nitric oxide, heme oxygenase-1, and human leukocyte antigen-G. These properties make MSCs promising therapeutic candidates for the treatment of autoimmune diseases. Here, we review the preclinical studies of MSCs in animal models for systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, and experimental autoimmune encephalomyelitis, and summarize the underlying immunoregulatory mechanisms.
Adipose Tissue
;
Arthritis, Rheumatoid
;
Autoimmune Diseases*
;
B-Lymphocytes
;
Bone Marrow
;
Crohn Disease
;
Dendritic Cells
;
Dinoprostone
;
Encephalomyelitis, Autoimmune, Experimental
;
Heme Oxygenase-1
;
Humans
;
Intercellular Signaling Peptides and Proteins
;
Interleukin-10
;
Leukocytes
;
Lupus Erythematosus, Systemic
;
Mesenchymal Stromal Cells*
;
Models, Animal*
;
Nitric Oxide
;
Placenta
;
Stem Cells
;
T-Lymphocytes
;
T-Lymphocytes, Regulatory
;
Umbilical Cord
7.Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells.
Ji Sung KIM ; Yong Guk KIM ; Eun Jae PARK ; Boyeong KIM ; Hong Kyung LEE ; Jin Tae HONG ; Youngsoo KIM ; Sang Bae HAN
Immune Network 2016;16(2):99-108
Colorectal cancer is the third leading cancer worldwide. Although incidence and mortality of colorectal cancer are gradually decreasing in the US, patients with metastatic colorectal cancer have poor prognosis with an estimated 5-year survival rate of less than 10%. Over the past decade, advances in combination chemotherapy regimens for colorectal cancer have led to significant improvement in progression-free and overall survival. However, patients with metastatic disease gain little clinical benefit from conventional therapy, which is associated with grade 3~4 toxicity with negative effects on quality of life. In previous clinical studies, cell-based immunotherapy using dendritic cell vaccines and sentinel lymph node T cell therapy showed promising therapeutic results for metastatic colorectal cancer. In our preclinical and previous clinical studies, cytokine-induced killer (CIK) cells treatment for colorectal cancer showed favorable responses without toxicities. Here, we review current treatment options for colorectal cancer and summarize available clinical studies utilizing cell-based immunotherapy. Based on these studies, we recommend the use CIK cell therapy as a promising therapeutic strategy for patients with metastatic colorectal cancer.
Cell- and Tissue-Based Therapy
;
Colorectal Neoplasms*
;
Cytokine-Induced Killer Cells*
;
Dendritic Cells
;
Drug Therapy, Combination
;
Humans
;
Immunotherapy*
;
Incidence
;
Lymph Nodes
;
Mortality
;
Prognosis
;
Quality of Life
;
Survival Rate
;
Vaccines
8.Investigation on the Frequency and Severity of Common Adverse Reactions of Japanese Encephalitis Vaccines.
Boo Young KIM ; Dong Hyun KIM ; Hun Jae LEE ; Soo Kyung JUNG ; Xiao Shan LI ; Un Yeong GO ; Sook Kyung PARK ; Young Jin HONG
Korean Journal of Pediatric Infectious Diseases 2009;16(2):183-190
PURPOSE: To evaluate the number and severity of adverse reactions after Japanese Encephalitis (JE) vaccination in children using different vaccines (inactivated vaccine or live attenuated vaccine) and to determine the ability and safety of the vaccines to provide effective immunization for JE. METHODS: From August 2006 to February 2007, we conducted a prospective cohort study of the adverse reactions associated with JE immunization in Korea. We investigated common adverse reactions during the 4 days following immunization using telephone collaborations with four public health centers and nine pediatric clinics. RESULTS: The mean age of children receiving the inactivated vaccines and live attenuated vaccines, respectively, were 1.4 y (range: 1 to 8.5) and 1.7 y (range: 1 to 8.3). The number of children that received the inactivated vaccines was 425 (64.6%). A total of 233 (35.4%) received the live attenuated vaccines. Fourteen children (3.3%) had more than one localized adverse event with the inactivated vaccine, and six (2.6%) had more than one event with the live attenuated vaccine (P=0.607). Systemic adverse reactions occurred in 5.2% vs. 8.2%, respectively, of these groups (P=0.131). Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination (P=0.026). CONCLUSIONS: The rate of adverse events in our study was even lower than that previously reported. No significant difference in outcomes between inactivated vaccine and live attenuated vaccine was found in JE-immunized children. Fever was more common in the live attenuated vaccine group than in the inactivated vaccine group on the day of vaccination.
Asian Continental Ancestry Group
;
Child
;
Cohort Studies
;
Cooperative Behavior
;
Encephalitis, Japanese
;
Fever
;
Humans
;
Immunization
;
Japanese Encephalitis Vaccines
;
Korea
;
Prospective Studies
;
Public Health
;
Telephone
;
Vaccination
;
Vaccines
;
Vaccines, Attenuated
;
Vaccines, Inactivated
9.Dendritic Cell Activation by Glucan Isolated from Umbilicaria Esculenta.
Hyung Sook KIM ; Jee Youn KIM ; Hong Kyung LEE ; Moo Sung KIM ; Sang Rin LEE ; Jong Soon KANG ; Hwan Mook KIM ; Kyung Ae LEE ; Jin Tae HONG ; Youngsoo KIM ; Sang Bae HAN
Immune Network 2010;10(6):188-197
BACKGROUND: Lichen-derived glucans have been known to stimulate the functions of immune cells. However, immunostimulatory activity of glucan obtained from edible lichen, Umbilicaria esculenta, has not been reported. Thus we evaluated the phenotype and functional maturation of dendritic cells (DCs) following treatment of extracted glucan (PUE). METHODS: The phenotypic and functional maturation of PUE-treated DCs was assessed by flow cytometric analysis and cytokine production, respectively. PUE-treated DCs was also used for mixed leukocyte reaction to evaluate T cell-priming capacity. Finally we detected the activation of MAPK and NF-kappaB by immunoblot. RESULTS: Phenotypic maturation of DCs was shown by the elevated expressions of CD40, CD80, CD86, and MHC class I/II molecules. Functional activation of DCs was proved by increased cytokine production of IL-12, IL-1beta, TNF-alpha, and IFN-alpha/beta, decreased endocytosis, and enhanced proliferation of allogenic T cells. Polymyxin B, specific inhibitor of lipopolysaccharide (LPS), did not affect PUE activity, which suggested that PUE was free of LPS contamination. As a mechanism of action, PUE increased phosphorylation of ERK, JNK, and p38 MAPKs, and enhanced nuclear translocation of NF-kappaB p50/p65 in DCs. CONCLUSION: These results indicate that PUE induced DC maturation via MAPK and NF-kappaB signaling pathways.
Dendritic Cells
;
Endocytosis
;
Glucans
;
Interleukin-12
;
Lichens
;
Lymphocyte Culture Test, Mixed
;
NF-kappa B
;
p38 Mitogen-Activated Protein Kinases
;
Phenotype
;
Phosphorylation
;
Polymyxin B
;
T-Lymphocytes
;
Tumor Necrosis Factor-alpha
10.Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy
Hyung Sook KIM ; Jae Seob LEE ; Hong Kyung LEE ; Eun Jae PARK ; Hye Won JEON ; Yu Jeong KANG ; Tae Yong LEE ; Kyung Suk KIM ; Sang Cheol BAE ; Ji Hyun PARK ; Sang Bae HAN
Immune Network 2019;19(5):e36-
Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.
Actins
;
Animals
;
Body Weight
;
Chitinase
;
Collagen
;
Creatinine
;
Doxorubicin
;
Fibronectins
;
Fibrosis
;
Inflammation
;
Mesenchymal Stromal Cells
;
Mice
;
Podocytes
;
Proteinuria